…
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Biophytis S.A. is a clinical-stage biotechnology company developing small-molecule therapies targeting age-related muscle weakness and respiratory disorders, with lead programs aimed at improving muscle and lung function. Long-term growth may be supported by demographic trends toward older populations, persistent unmet needs in sarcopenia and pulmonary disease, and advancement through clinical and regulatory milestones. Investors may find exposure to potentially high-impact clinical outcomes and a focused therapeutic niche attractive, while acknowledging binary program outcomes.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -10.38M | -18.59M | -24.22M | -31.25M | -17.05M |
| Minority interest | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net income | -10.38M | -17.03M | -24.22M | -31.16M | -25.52M |
| Selling general administrative | 5.12M | 5.49M | 7.24M | 7.15M | 4.02M |
| Selling and marketing expenses | - | 0.42M | 0.14M | 0.93M | 0.24M |
| Gross profit | 0.00M | -0.80M | -0.48M | -0.31M | -0.28M |
| Reconciled depreciation | 0.30M | 0.80M | 0.48M | 0.31M | 0.28M |
| Ebit | -8.50M | -14.33M | -23.52M | -26.82M | -13.94M |
| Ebitda | -8.26M | -13.80M | -23.04M | -26.50M | -13.66M |
| Depreciation and amortization | 0.24M | 0.53M | 0.48M | 0.31M | 0.28M |
| Operating income | -8.50M | -14.33M | -23.27M | -26.82M | -13.94M |
| Other operating expenses | 8.50M | 14.33M | 23.27M | 26.82M | 13.94M |
| Interest expense | 1.53M | 1.25M | 1.60M | 4.43M | 4.37M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -1.33M | -1.41M | -2.46M | -2.53M | -1.50M |
| Income tax expense | - | -1.56M | -1.52M | 2.28M | 4.37M |
| Total revenue | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 8.50M | 14.33M | 23.27M | 26.82M | 13.94M |
| Cost of revenue | 0.00M | 0.80M | 0.48M | 0.31M | 0.28M |
| Total other income expense net | -1.89M | -4.25M | -0.94M | -4.35M | -11.57M |
| Net income from continuing ops | -10.38M | -17.03M | -24.22M | -31.16M | -25.52M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 6.90M | 11.96M | 21.99M | 36.26M | 27.21M |
| Intangible assets | 2.61M | 2.64M | 2.65M | 2.76M | 2.67M |
| Other current assets | 3.85M | 0.18M | 2.16M | 1.42M | 5.66M |
| Total liab | 16.60M | 15.85M | 23.90M | 30.56M | 20.38M |
| Total stockholder equity | -9.67M | -3.86M | -1.88M | 5.74M | 6.86M |
| Other current liab | 6.52M | 3.36M | 2.10M | 4.83M | 6.23M |
| Common stock | 0.73M | 2.08M | 47.66M | 27.19M | 20.15M |
| Capital stock | 0.73M | 2.08M | 47.66M | 27.19M | 20.15M |
| Retained earnings | -10.38M | -19.38M | -47.91M | -49.11M | -17.05M |
| Other assets | - | 0.02M | 0.00M | 0.00M | - |
| Cash | 0.08M | 5.57M | 11.05M | 23.93M | 5.85M |
| Total current liabilities | 15.61M | 12.37M | 19.35M | 23.14M | 18.36M |
| Current deferred revenue | - | 0.18M | 0.18M | 0.17M | 0.01M |
| Net debt | 9.76M | 0.51M | 1.07M | -8.55M | 3.25M |
| Short term debt | 9.09M | 3.52M | 10.21M | 8.37M | 7.26M |
| Short long term debt | 6.48M | 3.47M | 7.48M | 8.15M | 10.81M |
| Short long term debt total | 9.84M | 6.08M | 12.13M | 15.38M | 9.10M |
| Other stockholder equity | 15.28M | 13.47M | -1.61M | 27.83M | 42.90M |
| Total current assets | 3.92M | 8.85M | 18.58M | 31.69M | 24.01M |
| Long term investments | 0.01M | 0.03M | 0.04M | 0.07M | 0.09M |
| Short term investments | 0.19M | 0.37M | 0.59M | 1.23M | 12.92M |
| Net receivables | 0.08M | 2.74M | 5.20M | 5.12M | 5.21M |
| Long term debt | - | 2.42M | 3.51M | 4.39M | 0.94M |
| Inventory | - | 0.00M | 1.57M | -0.71M | 0.03M |
| Accounts payable | 4.28M | 5.35M | 6.94M | 7.61M | 7.99M |
| Accumulated other comprehensive income | -15.30M | -0.03M | -0.03M | -0.07M | -14.01M |
| Non currrent assets other | 0.14M | 0.13M | 0.12M | 1.17M | 0.32M |
| Non current assets total | 2.98M | 3.11M | 3.41M | 4.57M | 3.20M |
| Capital lease obligations | 0.14M | 0.19M | 0.47M | 0.45M | 0.00M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | - | 0.37M | -0.02M | 12.16M | -12.71M |
| Total cashflows from investing activities | 0.01M | - | - | - | - |
| Net borrowings | 4.00M | - | - | - | - |
| Total cash from financing activities | 3.14M | 7.03M | 6.13M | 29.71M | 22.07M |
| Net income | -10.38M | -17.03M | -24.22M | -31.25M | -17.05M |
| Change in cash | -5.49M | -5.49M | -12.87M | 18.08M | -0.49M |
| Begin period cash flow | 5.57M | 11.05M | 23.93M | 5.85M | 6.34M |
| End period cash flow | 0.08M | 5.57M | 11.05M | 23.93M | 5.85M |
| Total cash from operating activities | -8.64M | -12.87M | -18.99M | -23.80M | -9.86M |
| Issuance of capital stock | - | 5.54M | 0.00M | 16.58M | 23.49M |
| Depreciation | 1.06M | 0.80M | 0.48M | 0.31M | 0.28M |
| Other cashflows from investing activities | 0.01M | - | - | - | - |
| Dividends paid | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to inventory | - | - | 0.40M | 1.30M | -2.65M |
| Change to account receivables | -1.36M | 1.67M | -0.40M | -1.30M | 2.65M |
| Other cashflows from financing activities | -0.09M | 1.14M | -1.29M | 12.84M | -6.17M |
| Capital expenditures | 0.00M | 0.22M | 0.14M | 0.34M | 0.21M |
| Change in working capital | -1.36M | -0.03M | -1.33M | 1.32M | 3.01M |
| Stock based compensation | 0.74M | 0.81M | 5.57M | 3.42M | 0.79M |
| Other non cash items | 1.30M | 2.56M | 0.51M | 0.48M | 4.52M |
| Free cash flow | -8.64M | -13.09M | -19.13M | -24.14M | -10.08M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| BPTSY Biophytis S.A. |
- -% |
0.40 | - | - | - | 2.27 | -0.42 |
| NVO Novo Nordisk A/S |
-0.54 1.36% |
38.90 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
520.66 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
2.34 0.25% |
923.34 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.
| Name | Title | Year Born |
|---|---|---|
| Mr. Stanislas Veillet Ph.D. | Chairman of the Board & CEO | 1965 |
| Mr. Waly Dioh Ph.D. | Chief Clinical Operating Officer | 1969 |
| Dr. Pierre J. Dilda Ph.D. | Chief Scientific Officer | 1970 |
| Dr. Rene Lafont | Scientific Advisor & Member of Scientific Advisory Board | 1946 |
| Dr. Rob van Maanen FFPM, M.B.A., M.D. | Chief Medical Officer | 1971 |
| Mr. Edouard Bieth | Chief Business Officer | 1980 |
| Ms. Chiara Baccelli | Chief Pharmaceutical Operations Officer & Quality Assurance Director | NA |
| Ms. _ Teylan | Financial Controller | NA |
| Mr. Christophe Courtillat | Chief Financial Officer | NA |
| Mr. Waly Dioh Ph.D. | Chief Operating Officer | 1969 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.